Growth through acquisitions Recent acquisition of Fluxion Biosciences and integration with Cell Microsystems positions the company to offer automated patch clamp and single-cell assay tools as a combined solution, suggesting upsell opportunities to labs needing end-to-end single-cell workflows and diversified technologies.

Regulatory readiness Launch of software for CellRaft AIR System enabling 21 CFR Part 11 compliance opens doors to customers in regulated environments (pharma, contract research) seeking compliant data integrity and audit trails, a key selling point for larger biotech accounts.

Global lab footprint With hundreds of labs globally relying on Fluxion and related platforms, targeted expansion can focus on mid to large CROs and academic networks expanding single-cell and patch-clamp capabilities, offering scalable solutions and training packages.

Funding and momentum Recent Series B funding and sustained product announcements signal financial strength and ongoing development, providing a compelling narrative for strategic partnerships, co-development deals, and grant-aligned procurement cycles.

Integrated tech stack Existing tech stack including Google Cloud, Salesforce, HubSpot, and WordPress indicates readiness for data-driven sales enablement, CRM-driven account targeting, and digital marketing campaigns to reach researchers and procurement decision-makers.